Drug intelligence / Profile preview

vehicle foam (Sorilux)

Development stage: Unknown
Lead developer: Stiefel
Administration: Topical

Overview

Vehicle foam (Sorilux) is the placebo control formulation used in clinical trials for Sorilux (calcipotriene foam, 0.005%), developed by Stiefel, a GSK Company. It is an aqueous-based emulsion foam designed to be chemically and physically identical to the active Sorilux product, excluding the active ingredient calcipotriene. This vehicle was utilized in Phase 3 randomized, double-blind studies to establish a baseline for the safety and efficacy of calcipotriene in the treatment of moderate plaque-type psoriasis affecting the scalp and body in both adult and pediatric populations.

Other names: Vehicle Foam

Beyond the preview

Go deeper on vehicle foam (Sorilux).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vehicle foam (Sorilux).

Explore the full profile